Ruxolitinib Is Under Investigation as JAK Inhibition Strategy for Multiple Myeloma
CancerNetwork® spoke with James R. Berenson, MD, founder, medical and scientific director, and president and…
read moreRuxolitinib Elicits Few Adverse Effects When Treating Multiple Myeloma
CancerNetwork® spoke with James R. Berenson, MD, president and medical director of the Berenson Cancer…
read moreRuxolitinib/Selinexor Combo Is Being Evaluated for Multiple Myeloma
Encouraging preclinical data foreground a clinical trial evaluating ruxolitinib (Jakafi) with selinexor (Xpovio) in patients…
read moreExploring the Potential Role of JAK Inhibitors in Multiple Myeloma
CancerNetwork® spoke with James R. Berenson, MD, about the potential role that JAK inhibitors may…
read moreLaunch of Myeloma BioBank
The Exciting Launch of Myeloma BioBank: James R. Berenson, MD, Multiple Myeloma, specialist announced in an interview…
read moreTargeted Oncology
Clinical Outcomes and Serum B-Cell Maturation Antigen Levels in a Real-World Unselected Population of Newly…
read moreAmerican Society of Hematology
Blood Journal: A Phase 1 Trial: Evaluating…Methylprednisolone: RE: ASH 2023 San Diego, CA December 9-11…
read moreMedPage Today
James R. Berenson, MD: Can JAK Inhibition Help Overcome Lenalidomide Resistance in Myeloma? Early-phase experience…
read moreHemOnc Today
Multiple Myeloma regimens significantly less effective in real-world treatment settings In this study, researchers looked…
read moreHealio Hematology & Oncology News
Interviewed Dr. Berenson on his perspective on Abstract 1 & Abstract 2. Questions: Reaction to…
read more